Czech/SlovakiaCzech RepublicSlovakia

Risks are Assessed Case-by-case

16.09.2003

The Czech Republic is in the eye of the storm in the confrontation between supporters and opponents of GMOs (see also page 20). EuroBiotechNews spoke with Libor Ambrozek, Minister for the Environment of the Czech Republic, about the postponed decision on Monsanto's application to approve of its Bt maize.

What were the reasons to hand the decision over to an independent expert group?
The administrative procedure of assessing the applications for the use of GMOs is in every case complex, that is to ensure that all the potential risks and benefits are considered. The Competent Authority handling the applications and regulating the use of GMOs in the Czech Republic is the Department of Environmental Risks at the Ministry of the Environment (MoE). It co-operates with the Ministry of Health in respect of risks for human health and with the Ministry of Agriculture as regards the agricultural risk, animal health, crops and feed stuffs. Advisory body to the MoE is the Czech Commission for the Use of GMOs and Products. The marketing approval for Monsanto´s Bt maize issued by the Department of Environmental Risks in March 2003 was rather limited. It covered only planting and processing, but not import and export of the maize. According to the opinion of the Ministry of the Agriculture, strict isolation distances were required for fields with Bt maize. Monsanto appealed against the restrictive conditions of the approval. On the opposite side, Greenpeace, appealed against the approval as such. Both appeals were examined by the committee of lawyers and I consequently repealed the approval because the conditions were insufficiently substantiated. The case was referred back to the department to re-negotiate and substantiate the conditions of the use of Bt maize with the Ministry of Agriculture.
Who is in this expert group and when do you expect a decision?
Members of the Commission for the use of GMOs are representatives of administrative authorities, scientists and representatives of NGOs. The list of the members is published on the website of the MoE. A new decision should be issued at the end of September.
How does the MoE consider the risks from 'cross-pollination'?
Risk are always assessed case-by-case. As far as maize is concerned, cross-pollination could present a risk to neighbouring farmers as regards potential contamination of their final product. The environmental risks considered to be low. Maize has no sexually compatible relatives in the indigenous flora of the Czech Republic. It does not survive winters and the seeds of maize used by farmers are hybrids, which refers to the special technology of seed production. To minimize potential economic losses from the admixtures of GM in non-GM crops, the Ministry of Agriculture in co-operation with the MoE prepares detailed guidelines for the coexistence of genetically modified crops with conventional and organic farming in accordance with the recommendation of European Commission from July 2003.
Can you characterize the public opinion on GM food in the Czech Republic?
Public opinion on GM food in the Czech Republic is about the same as in other European countries. The public supports labelling of GMO products. The genetically modified crops that are on the market in other countries do not bring any advantage for consumers, so the public does not see any specific reason to buy them.
Do you share environmentalists' claims that Monsanto uses the Czech Republic as a key to open the whole EU GMO market?
The applications for GM crops submitted by Monsanto in the Czech Republic and approved by the MoE are the same as in other EU member states. The MoE approved field trials with Bt maize MON 810, which has already been granted marketing approval in the EU, and field trials with Roundup Ready maize which is also tested in EU member states. Field trials with Roundup Ready wheat applied for by Monsanto have not been approved of. The marketing approval for Monsanto's Roundup Ready soybeans is equivalent to the authorization already granted in the EU.
Thank you very much, Mr. Ambrozek!

Czech/SlovakiaCzech RepublicSlovakia

21.02.2009

Prague – At a meeting with Czech stakeholders in Prague in December, EuropaBio expressed its appreciation that the Czech Republic is one of the ‘pro-biotech’ EU member states. In January when the Czech Republic took over the...

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D,...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/risks-are-assessed-case-by-case.html

Product of the week

Products

Events

All Events

Current issue

All issues